AqVida GmbH
About AqVida GmbH
Certifications
-
FDA -
GMP
Categories
-
DE -
2015On CPHI since
-
2Certificates
-
50 - 99Employees
Company types
Contact info
-
-
-
Kaiser-Wilhelm-Str. 89, D-20355 , Hamburg, Germany
Products from AqVida GmbH (14)
-
Product Azathioprine AqVida film-coated tablets
25 mg, 50 mg Tablets Immunosuppressant -
Product Docetaxel AqVida 20 mg/ml concentrate for solution for infusion
20 mg, 80 mg, 140 mg, 160 mg vial Indications: Treatment of breast cancer, special form of lung cancer, prostate cancer, gastric cancer and head or neck cancer -
Product Epirubicin AqVida 2 mg/ml solution for injection
10 mg, 20 mg, 50 mg, 100 mg, 200 mg vialIndications: Treatment of breast cancer, advanced ovarian cancer, stomach cancer, small cell lung cancer, bladder cancer -
Product Gemcitabine AqVida 38 mg/ml powder for solution for infusion
200 mg, 1 g, 2 g vial Indications: Treatment of NSCLC, pancreatic cancer, bladder cancer, breast cancer -
Product Imatinib AqVida hard capsules*
100 mg, 200 mg, 400 mg capsuleIndications: Treatment of chronic myeloid leukaemia, GIST * Products protected by valid patents are not offered in countries where the sale constitutes a patent infringement. -
Product Irinotecan AqVida 20 mg/ml concentrate for solution for infusion
40 mg, 100 mg, 300 mg vial Indications: Treatment of advanced colorectal cancer -
Product Leucita/Filgrastim AqVida (recombinant human G-CSF) solution for injection
75 mcg, 150 mcg, 300 mcg, 480 mcg vial Indications: Treatment of neutropenia, e.g. after a chemotherapy, severe chronic neutropenia or neutropenia in patients with HIV infections -
Product Oxaliplatin AqVida 5 mg/ml concentrate for solution for infusion
50 mg, 100 mg, 200 mg vialIndications: Treatment of advanced colorectal cancer -
Product Paclitaxel AqVida 6 mg/ml concentrate for solution for infusion
30 mg, 100 mg, 150 mg, 300 mg vial Indications: Treatment of ovarian cancer, breast cancer, advanced NSCLC, AIDS-related Kaposi‘s sarcoma -
Product Pemetrexed AqVida 25 mg/ml powder for solution for infusion*
100 mg, 500 mg, 1 g vialIndication: Treatment of NSCLC
* Products protected by valid patents are not offered in countries where the sale constitutes a patent infringement. -
Product Sunitinib AqVida hard capsules*
12.5 mg, 25 mg, 37.5 mg, 50 mg CapsuleIndications: Treatment of mRCC, GIST * Products protected by valid patents are not offered in countries where the sale constitutes a patent infringement. -
Product Azacitidin AqVida 25 mg/ml concentrate for solution for infusion
Filling Sizes: 100 mg; 150 mg
AqVida GmbH Resources (1)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance